Sign in

NCT05753059RecruitingPhase 1

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Source: ClinicalTrials.gov · Last updated 8 Sept 2026

Brief summary (registry, in English)

Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
50 (estimated)
First submitted
21 Feb 2023
Start date
10 Aug 2023
Primary completion date
1 Jun 2028
Lead sponsor
Yale University
NCT number
NCT05753059

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 50
  • From 10 Aug 2023 to the primary completion date, 1 Jun 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of flash pulmonary edema requiring hospitalization and treatment with biphasic positive airway pressure or mechanical ventilation or a "brittle" volume sensitive HF phenotype such as an infiltrative or restrictive cardiomyopathy (i.e. amyloid cardiomyopathy, etc).
  • On Lithium therapy

Other illness

  • Diagnosis of liver failure
  • Contraindications or allergy to sulfonamides
  • Any contraindication to thiazide diuretic or allergy to thiazide or bendroflumethiazide

Lab values

  • GFR \<20 ml/min/1.73m2 using the CKD-EPI equation or use of renal replacement therapies
  • Hemoglobin \< 8 g/dL or symptomatic anemia

Other

  • Use of any non-loop type diuretic in the last 7 days or 5 half lives, with the exclusion of low dose aldosterone antagonist (e.g., spironolactone or eplerenone ≤50 mg). Examples of non-loop diuretics include but may not be limited to acetazolamide (oral or IV, not ophthalmic), metolazone, HCTZ, chlorthalidone, chlorothiazide, indapamide, triamterene, amiloride, finerenone, spironolactone dose \> 50mg day, eplerenone \> 50mg/day,
  • Pregnant or breastfeeding
  • Inability to give written informed consent or comply with study protocol or follow-up visits
  • Chronic urinary retention limiting ability to perform timed urine collection procedures
  • On pimozide or thioridazine

Who the study is looking for

  • Clinical diagnosis of HF
  • No plan for titration/change of heart failure medical or device therapies during the study period.
  • Absence of non-elective hospitalizations in the previous 2 weeks
  • At optimal volume status by symptoms, exam, and dry weight.
  • Serum potassium ≤ 5.0 mmol/L
  • Serum sodium ≥ 130 mEq/L
  • Age \> 18 years
  • Hemoglobin ≥8 g/dL
  • Objective evidence of diuretic resistance to a 10mg bumetanide challenge, defined as:
    • FENa \<10% and total sodium output \<150mmol and
    • At least one of the following criteria:
    • 1\. Chronic home furosemide dose \> or equal to 80mg furosemide equivalents daily 2. eGFR \< 60ml/min 3. Serum chloride \<100mmol/L 4. FENa \<5% and total sodium output \<75mmol on the 2 hour screening

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Yale University
Coordinator of this site? Confirm its status
New HavenUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.